You are here: Home » PTI Stories » National » News
Business Standard

SPARC stock ends nearly 6% lower on spasticity study results

Press Trust of India  |  New Delhi 

of Sun Pharma Advanced Research Company (SPARC) today ended nearly 6 per cent lower after the company said its pivotal studies on treatment of spasticity in patients with multiple sclerosis did not meet the desired outcome.

The stock dived 5.82 per cent to settle at Rs 366.70 on During the day, it tumbled 14.72 per cent to Rs 332.

At NSE, of the company plunged 5.59 per cent to end at Rs 367.10.

The company's market valuation also declined by Rs 558.32 crore to Rs 9,053.68 crore.

In terms of equity volume, 12.88 lakh of the company were traded on and over 54 lakh shares changed hands at during the day.

Baclofen GRS is a novel, once-a-day formulation developed by the company's proprietary gastroretentive system (GRS) technology, SPARC said in a filing to on Friday.

SPARC CEO Anil Raghavan had said: "We are disappointed with the outcomes of these studies and will evaluate the data in greater detail to decide on our next steps.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Mon, October 09 2017. 17:22 IST